Form 4: NeuroOne Medical Technologies Executive Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 906 shares of common stock on March 31, 2025, to cover tax obligations.

Summary

  • On March 31, 2025, Steve Mertens, the Chief Technology Officer of NeuroOne Medical Technologies Corp, disposed of 906 shares of common stock.
  • The transaction was executed at a price of $0.8502 per share.
  • This disposal was conducted to cover tax obligations related to equity compensation.
  • Following the transaction, Mertens directly owns 163,141 shares of NeuroOne Medical Technologies Corp.
  • The transaction was reported on April 2, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects a routine transaction to cover tax obligations. It doesn't indicate any significant positive or negative outlook for the company.

Industry Context

This is a routine transaction for executives to cover tax obligations related to stock-based compensation. It doesn't necessarily reflect a change in the executive's confidence in the company.

Stakeholder Impact

  • The transaction is unlikely to have a significant impact on shareholders, as it is a small percentage of the total outstanding shares.

Key Dates

DateDescription
03/31/2025Date of transaction: Steve Mertens disposed of 906 shares of common stock.
04/02/2025Date of Form 4 filing.

Keywords

NeuroOne Medical Technologies, NMTC, Steve Mertens, Chief Technology Officer, Form 4, Stock Sale, Tax Obligations, Insider Trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.